• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[全国针对C群脑膜炎球菌病的疫苗接种运动的首个效果:患者数量迅速且大幅下降]

[The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].

作者信息

de Greeff S C, de Melker H E, Spanjaard L, van den Hof S, Dankert J

机构信息

Rijksinstituut voor Volksgezondheid en Milieu, Centrum voor Infectieziekten Epidemiologie, Postbus 1, 3720 BA Bilthoven.

出版信息

Ned Tijdschr Geneeskd. 2003 Jun 7;147(23):1132-5.

PMID:12822525
Abstract

OBJECTIVE

To describe the initial effects of the large-scale vaccination campaign in June-July of 2002 (1-5- and 15-18-year-olds) and September-November of 2002 (6-14-year-olds) on the incidence of group-C meningococcal disease in the Netherlands.

DESIGN

Descriptive.

METHOD

The incidence of meningococcal disease and the serogroup distribution were determined on the basis of the patient data associated with isolates of Neisseria meningitidis that were sent to the Netherlands Reference Laboratory for Bacterial Meningitis during the period from 1 January 1999 to 31 January 2003.

RESULTS

The highest monthly incidence of serogroup-C disease was reported in January-April 2002 (2.2-3.1/100,000), after which the incidence remained more or less unchanged after September at a level of 0.1-0.4/100,000. The incidence of meningococcal-C disease was 73% lower in August-October 2002 compared with the same period in 2001. In the same months, the incidence of meningococcal-C disease for the 0, 1-5, 6-14, 15-18 and > 18 year-olds was 49%, 80%, 89%, 89% and 42%, respectively, lower than in the same months in the previous year. The percentage of meningococcal disease caused by serogroup-C fluctuated from 35 to 49% in January-August 2002 and decreased to 9-19% in September-December 2002. There was also a decrease in the unvaccinated age groups.

CONCLUSION

The vaccination campaign led almost immediately to a sharp decrease in the number of patients with meningococcal serogroup-C disease.

摘要

目的

描述2002年6月至7月(1 - 5岁及15 - 18岁人群)和2002年9月至11月(6 - 14岁人群)大规模疫苗接种运动对荷兰C群脑膜炎球菌病发病率的初步影响。

设计

描述性研究。

方法

根据1999年1月1日至2003年1月31日期间送往荷兰细菌性脑膜炎参考实验室的脑膜炎奈瑟菌分离株相关的患者数据,确定脑膜炎球菌病的发病率和血清群分布。

结果

2002年1月至4月报告的C群疾病月发病率最高(2.2 - 3.1/10万),此后9月之后发病率基本保持不变,维持在0.1 - 0.4/10万的水平。2002年8月至10月,脑膜炎球菌C群疾病的发病率比2001年同期低73%。在同一时期,0岁、1 - 5岁、6 - 14岁、15 - 18岁及18岁以上人群的脑膜炎球菌C群疾病发病率分别比上一年同期低49%、80%、89%、89%和42%。2002年1月至8月,C群引起的脑膜炎球菌病百分比在35%至49%之间波动,2002年9月至12月降至9%至19%。未接种疫苗的年龄组发病率也有所下降。

结论

疫苗接种运动几乎立即导致脑膜炎球菌C群疾病患者数量急剧下降。

相似文献

1
[The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients].[全国针对C群脑膜炎球菌病的疫苗接种运动的首个效果:患者数量迅速且大幅下降]
Ned Tijdschr Geneeskd. 2003 Jun 7;147(23):1132-5.
2
Meningococcal C vaccines: the Canadian experience.脑膜炎球菌C疫苗:加拿大的经验
Pediatr Infect Dis J. 2004 Dec;23(12 Suppl):S280-4.
3
[Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination].[马德里社区脑膜炎球菌病的演变。A+C 型抗脑膜炎球菌疫苗的有效性]
Rev Esp Salud Publica. 2000 Jul-Aug;74(4):397-403.
4
Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China.中国合肥市脑膜炎球菌病近期的流行病学变化可能是由于A血清群被C血清群取代所致。
Postgrad Med J. 2008 Feb;84(988):87-92. doi: 10.1136/pgmj.2007.065680.
5
Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.1993年至2006年希腊的C群脑膜炎球菌病:多数儿科医生采用的非官方单剂量疫苗接种方案的影响
Clin Microbiol Infect. 2007 May;13(5):550-2. doi: 10.1111/j.1469-0691.2007.01704.x. Epub 2007 Mar 22.
6
The impact of meningococcal serogroup C conjugate vaccine in Scotland.脑膜炎球菌C群结合疫苗在苏格兰的影响。
Clin Infect Dis. 2004 Aug 1;39(3):349-56. doi: 10.1086/421947. Epub 2004 Jul 19.
7
Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.用于从婴儿期起提供更广泛保护的四价ACYW-135脑膜炎球菌结合疫苗。
Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18.
8
Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.在大规模接种C群脑膜炎球菌多糖疫苗1年后加泰罗尼亚地区的脑膜炎球菌病情况
Infection. 2003 Dec;31(6):392-7. doi: 10.1007/s15010-003-3121-6.
9
The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.加拿大儿童C群脑膜炎球菌结合疫苗计划的影响
Pediatr Infect Dis J. 2009 Mar;28(3):220-4. doi: 10.1097/INF.0b013e31819040e7.
10
[Evolution of meningococcal infection among infant population in the autonomous community of Valencia (1996-2000). Effectiveness of A+C meningococcal vaccination].[巴伦西亚自治区婴儿群体中脑膜炎球菌感染的演变(1996 - 2000年)。A + C型脑膜炎球菌疫苗接种的有效性]
Rev Esp Salud Publica. 2003 Jan-Feb;77(1):125-42.

引用本文的文献

1
Public health impact and cost-effectiveness of introducing MenACWY vaccination strategies in Germany.在德国引入A群脑膜炎球菌结合疫苗(MenACWY)接种策略的公共卫生影响和成本效益
BMC Public Health. 2025 May 5;25(1):1653. doi: 10.1186/s12889-025-21491-3.
2
Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.欧洲脑膜炎球菌疫苗接种的不断演变策略:概述及当前与未来考量的关键决定因素
Pathog Glob Health. 2022 Mar;116(2):85-98. doi: 10.1080/20477724.2021.1972663. Epub 2021 Sep 27.
3
Changing Epidemiology of Bacterial Meningitis Since Introduction of Conjugate Vaccines: 3 Decades of National Meningitis Surveillance in The Netherlands.
自结合疫苗问世以来细菌性脑膜炎的流行病学变化:荷兰 30 年全国脑膜炎监测。
Clin Infect Dis. 2021 Sep 7;73(5):e1099-e1107. doi: 10.1093/cid/ciaa1774.